Benefit of Adjuvant Chemotherapy for Resected Pancreatic Cancer Following Neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: A Multinational Analysis
V. Lopez LopezClinic and University Hospital Virgen de la Arrixaca, IMIB-Pascual Parrilla, Murcia, SpainT. HasseUniversity Hospital Zurich, Zurich, SwitzerlandE. RangelovaUniversity of Gothenburg, Gothenburg, SwedenG. MalleoUniversity of Verona, Verona, ItalyS.-G. LeeUniversity of Ulsan College of Medicine, Seoul, Republic of KoreaS. AbdurakhmonovKarshi State University, Karshi, UzbekistanS.H. PatelThe University of Cincinnati College of Medicine, Cincinnati, United StatesR.K. SchmockerUniversity of Tennessee Graduate School of Medicine, Knoxville, United StatesR.F. PalmThe Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Ohio, United StatesS.E. HoffeH. Lee Moffitt Cancer Center & Research Institute, Florida, United StatesJ. HeJohns Hopkins Hospital, Baltimore, United StatesN. PuZhongshan HospitalB. IelpoHospital del Mar, Barcelona, SpainP. BeltranUniversity Hospital Juan Ramon Jimenez, Huelva, SpainI. JustoHospital 12 de Octubre, Madrid, SpainK. DajaniUniversity of Alberta, Edmonton, CanadaJ. SobirovA. PascheUniversity Hospital Muenster, Muenster, GermanyC. YooUniversity of Ulsan College of Medicine, Seoul, Republic of KoreaR. Robles-CamposHospital Universitario Virgen de la ArrixacaD. EshmuminovUniversity Hospital Zurich, Zurich, Switzerland
2026en
Ochiq kirishBronza
ABI
Annotatsiya
Annotatsiya mavjud emas.
Identifikatorlar
Iqtiboslar va manbalar
0 ta iqtibos0 ta foydalanilgan manba